Pricing Log in Create free account
Saturday 17 October 2026 Export ABT’s income statement to Excel — free account

Abbott Laboratories

ABT Healthcare Medical Devices

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024. In the quarter to June 2026, revenue grew 13.0%, EPS fell 47.5%, free cash flow grew 28.9% and total debt rose 142.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

104.88 0.20 +0.19%
Market cap
$181.1B
P/E
33.9×
Fwd P/E
22.9×
Dividend yield
2.40%
F-score
5/9
Altman Z
5.61
Beneish M
−2.50
Dividend safety
62/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Abbott Laboratories 10-Q filed Jul 28, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:02 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 29, 2026: 3 added · 1 removed · 24 modified; 3 with only figures updated

  1. Modified · Financial Review — Results of Operations

    The following tables detail sales by reportable segment for the three and six months ended March 31June 30. Percent changes are versus the prior year and are based on unrounded numbers.

27 more changes in this Item, word by word, in Powerpack.

Powerpack